Regeneron Pharmaceuticals (REGN) Stock Chart & Stock Price History $658.48 -4.14 (-0.62%) Closing price 03/21/2025 04:00 PM EasternExtended Trading$662.95 +4.47 (+0.68%) As of 03/21/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Regeneron Pharmaceuticals Stock Price Performance 5 Day Performance-0.97%1 Month Performance-5.98%3 Month Performance-7.92%6 Month Performance-39.70%Year-To-Date Performance-7.56%1 Year Performance-31.92% Receive REGN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address REGN Stock Chart for Monday, March, 24, 2025 REGN Chart by TradingViewRemove Ads Regeneron Pharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization03/21/2025$662.62$658.48-0.62%$661.00$651.061.87 million shs$71.99 billion03/20/2025$672.36$662.62-1.45%$674.83$662.33662,954 shs$72.44 billion03/19/2025$664.96$672.36+1.11%$674.57$659.03675,613 shs$73.51 billion03/18/2025$678.42$664.96-1.98%$678.27$664.30608,052 shs$72.70 billion03/17/2025$666.87$678.42+1.73%$679.83$664.68942,881 shs$74.17 billion03/14/2025$680.61$666.87-2.02%$686.98$657.001.31 million shs$72.91 billion03/13/2025$689.50$680.61-1.29%$698.95$677.34863,695 shs$74.41 billion03/12/2025$718.16$689.50-3.99%$712.46$683.43807,980 shs$75.38 billion03/11/2025$744.83$718.16-3.58%$747.70$712.391.11 million shs$78.51 billion03/10/2025$707.51$744.83+5.27%$748.29$709.381.63 million shs$81.43 billion Get the Latest News and Ratings for REGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 03/07/2025$698.44$707.51+1.30%$729.75$696.431.08 million shs$77.35 billion03/06/2025$687.15$698.44+1.64%$701.00$682.26866,396 shs$76.36 billion03/05/2025$675.49$687.15+1.73%$692.79$673.15828,674 shs$75.12 billion03/04/2025$684.87$675.49-1.37%$697.46$672.501.20 million shs$73.85 billion03/03/2025$698.74$684.87-1.99%$704.64$683.46708,523 shs$74.87 billion02/28/2025$702.78$698.74-0.57%$708.58$693.711.03 million shs$76.39 billion02/27/2025$706.94$702.78-0.59%$721.00$700.67568,430 shs$76.83 billion02/26/2025$723.47$706.94-2.28%$721.41$701.07712,848 shs$77.29 billion02/25/2025$713.25$723.47+1.43%$739.00$715.501.05 million shs$79.09 billion02/24/2025$700.33$713.25+1.84%$725.00$700.43896,401 shs$77.98 billion Related Companies Amgen Stock Price Chart Gilead Sciences Stock Price Chart Vertex Pharmaceuticals Stock Price Chart Alnylam Pharmaceuticals Stock Price Chart Biogen Stock Price Chart United Therapeutics Stock Price Chart BioMarin Pharmaceutical Stock Price Chart Incyte Stock Price Chart Neurocrine Biosciences Stock Price Chart Exelixis Stock Price Chart Receive REGN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:REGN) was last updated on 3/24/2025 by MarketBeat.com Staff From Our PartnersTrump Shock to change everything Is this Trump’s next major move? Millionaire trading expert Imre Gams has found a bill that directs the Uni...Centurion Publishing | SponsoredElon Musk’s NEW Project… RevealedYou won't believe what Elon Musk is hiding… Inside this facility in the middle of an industrial zone of Memphi...InvestorPlace | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.